Intranasal delivery of transferrin conjugated chitosan nanoparticles to the brain: A comparative analysis of conjugated and un-conjugated nanoparticles in vivo

IF 4.5 3区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Drug Delivery Science and Technology Pub Date : 2025-02-01 DOI:10.1016/j.jddst.2024.106550

Annu , Ali Sartaj , Zufika Qamar , Eman Aldosari , Sanjula Baboota , Javed Ali

{"title":"Intranasal delivery of transferrin conjugated chitosan nanoparticles to the brain: A comparative analysis of conjugated and un-conjugated nanoparticles in vivo","authors":"Annu , Ali Sartaj , Zufika Qamar , Eman Aldosari , Sanjula Baboota , Javed Ali","doi":"10.1016/j.jddst.2024.106550","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The current research aims to design transferrin (Tf) conjugated chitosan (CH) nanoparticles (NPs) of lurasidone hydrochloride (LH) for schizophrenia.</div></div><div><h3>Methods</h3><div>Ionic gelation technique was adopted to produce CH-NPs followed by Tf-thiolation. Designed NPs were assessed for <em>in vitro</em> drug release and <em>in vivo</em> pharmacokinetics studies to assess their brain-targeting efficiency. The efficacy and safety of designed NPs were evaluated in ketamine-induced Wistar rats.</div></div><div><h3>Results</h3><div><em>In vitro</em> drug release revealed supremacy of optimized NPs over LH-suspension owing to higher and sustained release of LH. A remarkable growth in drug concentration to the brain was discerned from designed NPs in comparison to LH-solution after intranasal administration (IN). A, marked increment in the antipsychotic potential of LH from NPs with enhanced anti-inflammatory and neuroprotective potential in comparison to LH-solution was observed.</div></div><div><h3>Conclusion</h3><div><em>In vivo,</em> results established the primacy of optimized NPs in inflating the brain delivery and therapeutic prospect of LH.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"104 ","pages":"Article 106550"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Delivery Science and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S177322472401219X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The current research aims to design transferrin (Tf) conjugated chitosan (CH) nanoparticles (NPs) of lurasidone hydrochloride (LH) for schizophrenia.

Methods

Ionic gelation technique was adopted to produce CH-NPs followed by Tf-thiolation. Designed NPs were assessed for in vitro drug release and in vivo pharmacokinetics studies to assess their brain-targeting efficiency. The efficacy and safety of designed NPs were evaluated in ketamine-induced Wistar rats.

Results

In vitro drug release revealed supremacy of optimized NPs over LH-suspension owing to higher and sustained release of LH. A remarkable growth in drug concentration to the brain was discerned from designed NPs in comparison to LH-solution after intranasal administration (IN). A, marked increment in the antipsychotic potential of LH from NPs with enhanced anti-inflammatory and neuroprotective potential in comparison to LH-solution was observed.

Conclusion

In vivo, results established the primacy of optimized NPs in inflating the brain delivery and therapeutic prospect of LH.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drug Delivery Science and Technology 医学-药学

CiteScore

8.00

自引率

8.00%

发文量

879

审稿时长

94 days

期刊介绍： The Journal of Drug Delivery Science and Technology is an international journal devoted to drug delivery and pharmaceutical technology. The journal covers all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines, gene delivery, tissue engineering, etc. Hot topics, related to manufacturing processes and quality control, are also welcomed.